Welcome to our dedicated page for Remsleep Holding SEC filings (Ticker: RMSL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The REMSleep Holdings, Inc. (RMSL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a public issuer focused on medical devices for sleep apnea and respiratory therapy. Here you can review REMSleep’s periodic and current reports to understand its financial condition, risks, and progress in commercializing CPAP interface products such as the DELTAWAVE Nasal Pillows System.
Key filings to watch include annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which typically contain management’s discussion and analysis, financial statements, and updates on regulatory, manufacturing, and commercialization activities. For example, REMSleep has filed a Form 12b‑25 (NT 10‑Q) to notify investors of a delayed Form 10‑Q for the period ended September 30, 2025, citing the need for additional time for its independent registered public accounting firm to complete its review and indicating an intention to file within the allowed extension window.
Investors can also use this page to track current reports on Form 8‑K (when filed), which may discuss material events such as regulatory clearances, significant agreements, or other developments related to the Deltawave CPAP pillows interface and future product pipeline. Ownership changes and insider transactions, when reported on Form 3, Form 4, or Form 5, help provide transparency into trading by directors, officers, and large shareholders.
Stock Titan enhances these documents with AI‑powered summaries that highlight key points from lengthy filings, helping readers quickly identify important disclosures without reading every page. Real‑time updates from the SEC’s EDGAR system ensure that new REMSleep filings appear promptly, while structured access to 10‑K, 10‑Q, 8‑K, and Form 4 reports supports deeper analysis of the company’s regulatory and financial history.
REMSleep Holdings (RMSL) reported Q3 2025 results showing a much larger loss while beginning sales of its DeltaWave CPAP interface. Revenue for the quarter was $7,454, down from $37,260 a year earlier, and the quarterly net loss widened to $2,312,146. For the first nine months of 2025, revenue was $12,278 versus $122,735 in 2024, with a net loss of $2,685,406 and an accumulated deficit of $17,956,162.
Results were heavily affected by a $2,160,000 non-cash compensation expense from issuing Series C preferred stock to the CEO and a related party. The company relies on multiple convertible promissory notes from 1800 Diagonal, which generated significant interest expense and share issuances totaling 73,214,713 shares in the period. At September 30, 2025, cash was $343,948 and net cash used in operating activities was $373,395. Management states there is substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 1,617,658,094 as of November 18, 2025.
RemSleep Holdings, Inc. filed a Form 12b-25 to notify a late filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company cites the need for additional time for its independent registered public accounting firm to complete its review.
RemSleep states it intends to file the Form 10-Q by or before November 19, 2025, consistent with the Rule 12b-25 provision that permits a five-calendar-day extension for quarterly reports.